MassDevice Q&A

June 30, 2009 by MassDevice staff

Q&A Features

11/02/2010 by Brian Johnson

William Hawkins, chairman and CEO of Medtronic Inc., dishes on mergers and acquisitions, the Food & Drug Administration and healthcare reform.

MassDevice Podcast: Medtronic CEO William Hawkins

For William Hawkins, Medtronic Inc. (NYSE:MDT) runs in the family.

Inside his corner office at the Fridley, Minn.-based medical device goliath, Hawkins, chairman and CEO of one of the world's largest medical device companies, keeps a picture of two customers he says not only shaped how he sees his company but how he sees the world.

One is Hawkins' father, who has had multiple Medtronic stents implanted. The the other is of his late uncle, a World War II veteran and Parkinson's disease sufferer who underwent deep brain stimulation therapy at the age of 87. It...

10/18/2010 by Brian Johnson

Listen to MassDevice.com's podcast with InfraReDx CEO Dr. James Muller, as he discusses the difficulty of finding financial backers to believe in his technology, the technology behind the IVUS "vulnerable plaque" imaging device and how innovative medical technologies can help drive down the cost of healthcare.

MassDevice Podcast: InfraReDx CEO Dr. James Muller

InfraReDx Inc. is on a roll this fall. The Burlington, Mass.-based medical device maker won 510(k) clearance from the Food...

08/23/2010 by Christian Holland

Absorption Systems CEO Patrick Dentinger dishes on growing a contract research organization amidst a recession and parlaying his drug testing business into the medical device development arena.

MassDevice Q&A: Absorption Systems CEO Patrick Dentinger

Absorption Systems LP is well-positioned in several sense of the word. The Exton, Pa. and San Diego-based contract research organization managed to expand during the Great Recession, buying medical device toxicology firm Perry Scientific last summer.

President and CEO Patrick Dentinger told MassDevice that his 100-employee firm, which profiles the absorption of pharmaceuticals into the human body before the drugs go to clinical testing, has barely had to paddle to catch a growing wave of...

08/16/2010 by Brad Perriello

Euan Thomson, president and CEO of Accuray Inc., on how his company managed to fare well despite the capital expenditure market's downturn, its distribution and R&D deal with Siemens and why healthcare reform could have a big upside for Accuray.

MassDevice Q&A: Accuray president and CEO Euan Thomson

Accuray Inc. (NSDQ:ARAY) has a tough row to hoe: Cultivate a market that crosses medical specialty lines for a product that costs millions. The Sunnyvale, Calif.-based company's CyberKnife system is a pioneering device in radiosurgery, using precisely targeted, massive doses of X-ray radiation to non-invasively destroy tumors.

Founded in the 1990, Accuray's device was based on an idea developed by a team of physicians at Stanford University, led by Dr. John Adler, in the late 1980s. Since its founding the company has seen its share of ups and downs, not least...

07/26/2010 by Brad Perriello

Rob Lyles, who heads up Cook Medical's peripheral intervention business, on the company's origins in a two-bedroom apartment, the impact of gift bans on the medical device industry and developments in treating diseased blood vessels in the legs.

MassDevice Q&A: Cook Medical vice president Rob Lyles

Cook Medical Group and Boston Scientific Corp. (NYSE:BSX) both got their start with catheter-based devices, but the medical device giants' similarities don't stop there. As Boston Scientific founder John Abele told MassDevice last month, his firm got its start in an unlikely place: the basement of a Catholic Church in Belmont, Mass.

Cook, the world's largest privately held medical device maker, had similarly humble origins. Founders Bill and Gayle Cook started their company out of one of the two bedrooms of their Bloomington, Ind., apartment in 1963. Rob Lyles, vice president and global leader of Cook Medical’s...

07/09/2010 by Christian Holland

Abiomed president and CEO Michael Minogue on his company's Impella heart pump and its prospects for gaining a larger share of the cardiac assist market.

MassDevice Q&A: Abiomed CEO Michael Minogue

Abiomed Inc. (NSDQ:ABMD) makes cardiac assist devices powerful enough to pump more than a gallon of blood through the heart each minute and small enough to be placed inside the heart via catheter. It's a highly specialized, highly competitive market that's difficult to break into.

At an investors meeting in Boston last week, the company sought to deliver the message that its devices offer a less invasive option than ventricular assist devices and don't need to be combined with inotropic drugs as is often the case with intra-aortic balloon pumps. It's been two years since Abiomed won 510(k) clearance from the Food & Drug...

Syndicate content
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp